Climb Bio (CLYM) Share-based Compensation (2020 - 2026)
Climb Bio's (CLYM) quarterly Share-based Compensation came in at $1.6 million in Q1 2026, down 20.62% YoY from $2.0 million in Q1 2025, and down 79.52% on a QoQ basis from $7.8 million in Q4 2025.
Climb Bio (CLYM) Share-based Compensation (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Share-based Compensation data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Share-based Compensation fell 20.62% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.5 million (up 75.4% YoY) and the FY2025 annual result came in at $11.7 million, up 110.55% from the prior year.
- Share-based Compensation slipped to $1.6 million in Q1 2026, from $7.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $10.2 million in Q3 2025 to a low of $313000.0 in Q1 2023.
- A 5-year average of $2.3 million and a median of $1.6 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 418.86% — and 2023, when it sank 79.69%.
- Tracing CLYM's Share-based Compensation over 5 years: stood at $1.8 million in 2022, then sank by 32.59% to $1.2 million in 2023, then surged by 37.94% to $1.7 million in 2024, then surged by 372.74% to $7.8 million in 2025, then slumped by 79.52% to $1.6 million in 2026.
- The last three Share-based Compensation figures came in at $1.6 million (Q1 2026), $7.8 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 19.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.50 Mn |
| Jun 30, 2026 | 19.50 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 7.84 Mn |
| Dec 31, 2025 | 7.84 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 512,000.00 |
| Jun 30, 2024 | 512,000.00 |
| Mar 31, 2024 | 465,000.00 |
| Mar 31, 2024 | 465,000.00 |